The Konya Declaration for Patients with Primary Immunodeficiencies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Registry-Based Frequency and Clinical Characteristics of Inborn Errors of Immunity in Kazakhstan: A Retrospective Observational Cohort Study (2009-2023).Journal of clinical medicine · 2025
   Article
2. Through Education and Collaboration to Better Care for Primary Imunodeficiencies in Albania and Kosovo.Journal of clinical immunology · 2023
   Article
3. Editorial: Advances in primary immunodeficiencies (inborn errors of immunity) in Central-Eastern Europe, volume II.Frontiers in immunology · 2023
   Article
4. Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021.Frontiers in immunology · 2022
   Article
5. Editorial: Advances in Primary Immunodeficiency in Central-Eastern Europe.Frontiers in immunology · 2021
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as